The Iran's Islamic Revolutionary Guard Corps (IRGC) announced it will target US companies in the Middle East starting today (1st) as retaliation for actions against Iran by these companies, an Iranian state-run media outlet reported.

The 18 named companies include Microsoft (MSFT.US), Google under Alphabet (GOOGL.US), Apple (AAPL.US), Intel (INTC.US), IBM (IBM.US), Tesla (TSLA.US), and Boeing (BA.US).

The IRGC stated that these companies should expect attacks on their respective departments starting at 8 PM, Iran time, today (12:30 AM on April 2, Hong Kong time) owing to their terroristic actions against Iran.
~



AASTOCKS Financial News
Website: www.aastocks.com

Amid concerns over AI prospects, Microsoft (MSFT.US) stock price plunged 23% in the first quarter of this year, marking the largest quarterly slump since the 2008 financial crisis, far more than the declines of other tech peers and the Nasdaq's 7% drop.

Microsoft shares rebounded with the market on Tuesday, closing up 3.1%, the largest single-day gain since July. However, for the entire quarter, the cumulative downfall was as high as 23%, sharply underperforming the market.
~



AASTOCKS Financial News
Website: www.aastocks.com

US bourse leapfrogged Tuesday as investors were hopeful that the US-Iran war may soon come to an end. The Nasdaq closed up 795 points or 3.8%, at 21,590; the S&P 500 lifted 184 points or 2.9%, closing at 6,528; and the DJIA also soared 1,125 points or 2.5%, closing at 46,341.

Both the US and Iran were inclined to end the war, as US President Donald Trump reportedly told aides that he is willing to end military hostilities in the Middle East even if the Strait of Hormuz remains closed. Iranian President Masoud Pezeshkian is also reportedly willing to ceasefire if guarantees are provided.

With the conclusion of Iran war around the corner, the global tourism industry was envisioned to recover, with United Airlines (UAL.US) and Carnival Corporation (CCL.US) each surging by 8%.

Tech stocks experienced a revival on Tuesday, with the State Street Technology Select Sector SPDR ETF (XLK.US) up over 4%. NVIDIA (NVDA.US) planned to invest USD2 billion in Marvell (MRVL.US), with the latter's stock price swelling 13% and NVIDIA spiking 5.6%. Microsoft (MSFT.US) mounted 3.1%.
~



AASTOCKS Financial News
Website: www.aastocks.com

「金沙藝廊」展區獲國際高度肯定   澳門新銳藝術實力嶄露國際藝壇
延伸炮竹講座與社區參與   促澳門文化與世界交流互鑑

澳門2026年3月31日 /美通社/ -- 金沙中國於香港年度國際藝術盛會「藝術中環」（Art Central）設立的「金沙藝廊」展區於3月29日圓滿落幕。展區一連五日氣氛熾熱，匯聚國際畫廊代表、收藏家及藝術家駐足交流，圍繞三位澳門青年藝術家——李英維、梁子毛及廖克敏的創作展開跨文化深入交流；同場展示現於澳門「金沙藝廊」舉辦的《流光溢彩‧益隆百年》澳門炮竹時代記憶與美學特展之圖鑑及炮竹包裝招紙珍品，亦吸引大批國際觀眾到訪細賞，印證澳門跨時代文化的國際吸引力。是次參展充分發揮「金沙藝廊」作為澳門國際文化窗口的橋樑角色，引領本澳藝術家於國際舞台嶄露光芒，亦讓世界感受澳門淳厚文藝底蘊之美，成功提升了澳門文化藝術的國際知名度與影響力。

金沙中國為澳門首家以「聯合合作伙伴」身份受邀參與香港年度國際藝術盛會「藝術中環」的綜合旅遊休閒企業。藝術中環本屆規模創歷屆之最，匯聚117間畫廊及逾500位國際藝術家，吸引逾40,000觀眾人次。

自2022年成立以來，「金沙藝廊」持續引進國際藝術佳作，並為本澳藝術家搭建國際展示平台，全力配合澳門特區政府多元發展方向，推動文旅融合。是次進駐藝術中環，藝廊聚焦呈獻本澳三位當代藝術家的代表作品、以及澳門炮竹招紙原稿等合共逾40件展品；並延伸舉辦炮竹美學講座及組織藝術導賞，進一步促進澳門文化藝術與世界交流互鑑。

金沙中國有限公司行政副主席王英偉博士表示：「我們非常榮幸以聯合合作伙伴身份參與藝術中環，並衷心感謝主辦方對『金沙藝廊』的肯定與支持。藝術中環是全球當代藝術界極具影響力的平台，藝廊能躋身其中，向世界展現澳門文化厚度與藝術能量，並獲國際藝壇、學術界及參觀者廣泛肯定，意義深遠。是次參展，我們欣見李英維、梁子毛及廖克敏三位藝術家的創作深獲國際藏家、訪客及媒體的高度認可，助他們拓展國際視野與人際網絡，亦為其邁向更高水平的國際發展奠下良好基礎。我們亦延伸舉辦由吳衛鳴教授主講的炮竹美學專題講座，讓這段澳門百年歷史文化在交流分享中走進國際公眾的視野，並藉此文化名片吸引國際旅客來澳探古尋源，進一步鞏固澳門作為世界旅遊休閒中心的地位。謹此衷心感謝澳門特別行政區政府以及各界對藝廊的全力支持。未來，金沙中國將繼續全力配合澳門政府的多元發展方針，為本澳藝術家搭建更廣闊的國際舞台，以文藝力量，為澳門開拓一個更多元、更具遠見的未來。」

藝術中環展會總監Corey Andrew Barr表示：「金沙中國體現了一種超越傳統的伙伴精神，於澳門與香港之間建立真摯的藝術與思想交流渠道。這一切根植於兩城深厚的共同文化傳承，如同家人一樣緊密連結。 這是一個極具意義的合作，我們非常榮幸金沙中國成為藝術中環的聯合合作伙伴。」

藝術家李英維表示：「衷心感謝『金沙藝廊』悉力為澳門藝術家開拓國際視野，為我們提供了寶貴的展示機會。這次展出對我們幫助極大，有機會與多位國際收藏家及藝術機構取得聯繫，為澳門藝術家走向全球市場奠定重要基石。再次感謝金沙中國，希望未來能有更多機會參與國際藝術盛事，持續向世界展示並分享澳門藝術家的創作實力。」

藝術家梁子毛表示：「感謝金沙中國全力引薦我們參加藝術中環，使我們得以與國際畫廊、策展人及藝術家交流，更深入了解國際觀眾與市場的偏好。這次經歷為我提供豐富創作養分，也讓我思考澳門藝術與國際接軌的空間。從幾年前參與『藝文薈澳』於藝廊的平行展，到今天由藝廊引領我們站上此國際舞台，我深信『金沙藝廊』所凝聚的澳門藝文力量，未來將在世界藝壇綻放更大光芒。」

藝術家廖克敏表示：「感謝『金沙藝廊』讓我首次參與Art Central，這不僅是展示作品的機會，更是一段珍貴的學習與成長經歷。能在這個國際藝術平台上看到來自世界各地藝術家的創作與視角，令我深受震撼與啟發，也讓我重新思考自己的創作方向。藝術是一條沒有終點的路，這次經歷讓我更清晰確立目標，希望創作出更具感染力的作品，繼續用畫筆記錄生活、傳遞溫暖。」

場內觀展的法籍藝術家、收藏家Nicolas Deladerrière表示：「『金沙藝廊』於藝術中環的展示，精湛交融了傳統與當代藝術，令人耳目一新。澳門藝術家以精湛敏銳的視角解讀日常生活，巧妙呼應展區內的澳門百年美學脈絡。最令人難忘的是那些逾百載歲月的炮竹招紙原稿，它承載無數童年的共同回憶。而藝廊更以巧思將澳門歷史與新銳藝術並置，築起一道連接過去與未來的橋樑，觸動不同年代觀眾的心靈。」

延伸百年炮竹講座   呈現澳門文藝底蘊
為讓國際觀眾更好了解澳門百年炮竹業的美學概念，金沙中國特邀現於澳門「金沙藝廊」展出《流光溢彩‧益隆百年》澳門炮竹時代記憶與美學特展策展人、澳門科技大學人文藝術學院特聘教授吳衛鳴，於3月29日在藝術中環舉行專題講座。講座梳理炮竹業發展軌跡，並聚焦方寸包裝紙上的美學，剖析圖案背後的民間寓意與審美思潮，以及包裝設計如何回應跨文化市場需求。

講座現場反應熱烈，交流氣氛濃厚，講者的傾心分享，勾起港澳兩地的共同回憶，亦讓國際觀眾從產業歷史、美學設計與城市記憶之間，深入認識澳門炮竹文化的時代意義與人文溫度。

邀社服機構參與導賞   以藝術連結社區
為拓展澳門藝術觸達，公司特地邀請四家本澳社服機構，包括澳門扶康會、澳門特殊奧運會、挪亞家庭互助協會及澳門利民會之代表，前往香港藝術中環觀展及參與專業導賞。導賞團由藝術中環專業人員帶領，先後參觀「金沙藝廊」展區及其他參展畫廊，讓社服團體成員親身接觸國際藝術盛事，感受多元文化與創意的力量，並將國際藝術視野帶回澳門社區，促進藝術共融。

參與活動的澳門扶康會總幹事周惠儀表示：「感謝金沙中國為我們一眾社服機構安排是次導賞，讓我們見證『金沙藝廊』引薦三位澳門藝術家踏進『藝術中環』此國際藝壇盛事，並同時與國際頂尖藝廊交流。今次是藝術能量的吸收，我們得以更好了解國際藝術表達與展示技巧，對本會藝術發展具重要幫助。未來冀與本澳藝術家促成更多合作，共同推出藝術共融的產品，將澳門的故事及藝術帶到不同的地方。」

關於金沙藝廊
金沙藝廊為金沙中國旗下座落於澳門四季名薈的常設藝術空間，致力為澳門帶來豐富多元的藝術展覽，推動本澳文化創意產業的持續發展。

自2022年成立以來，藝廊已舉辦十二場風格多元的展覽，既引進國際及國家級規格的藝術作品，亦為本澳藝術家提供展示機會，助力他們接軌國際藝術舞台。

金沙中國藉由在藝術文化範疇持續投放資源，打造藝廊成為兼具藝術份量與文化深度的平台，為本澳注入多元文化力量，進一步豐富澳門居民及旅客的藝術體驗，提升大眾的藝術鑑賞能力；同時，全面配合特區政府推動非博彩發展的施政方針，助力澳門建設以中華文化為主流、多元文化共存的文化交流基地。

關於金沙中國有限公司
金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙酒店。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

關於藝術中環展會 
Art Central（藝術中環展會）是香港藝術周的重點盛事，展示亞洲最具生命力畫廊及新銳藝術家的前衛創作，以及全球藝壇巨匠的傑出作品。自2015年成立以來，展會已成為當代藝術創新的重要平台，助力藝術家與畫廊提升業界影響力，鞏固其在國際舞台上的地位。如今，展會以高水準的策展規劃備受認可，是全球私人、商業、機構藏家與策展人的重要匯聚地，為藝術探索與交流搭建至關重要的橋樑。

傳媒查詢：
金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected] 

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

上海2026年3月31日 /美通社/ -- 三生制藥（01530.HK）今日發布2025年度業績公告。三生制藥以創新研發突破與全球化戰略合作為雙輪核心驅動，交出一份量質齊升的高質量成績單：全年實現營業收入177.0億元，首次突破百億元大關，同比增長94.3%；歸母淨利潤84.8億元，同比增長305.8%；經調整歸母淨利潤84.5億元，同比增長264.6%，盈利能力實現跨越式躍升，彰顯強勁增長動能。

2025年，公司全年研發費用達15.2億元，同比增長14.6%，為創新管線推進提供堅實保障。截至2025年末，公司財務資源躍升至204.0億元，有息負債比率降至9.8%，綜合財務成本實現正向貢獻達2.3億元，資產負債結構進一步優化。充沛的現金流與穩健的資本結構為長遠發展築牢資金根基。公司延續穩定的分紅政策，派發2025年度股息0.25港幣/股，以扎實的股東回報傳遞長期發展信心。

報告期內，三生制藥與輝瑞達成總金額超60億美元的全球授權合作，獲得14億美元首付款及1億美元股權合作，創下中國創新藥出海首付款最高紀錄。核心產品特比澳®新適應症成功獲批，三款新藥接連獲批上市，三款產品進入NDA階段，構建多領域創新管線矩陣，全球化競爭力與核心治療領域優勢進一步夯實，為公司高質量發展注入強勁動力。

一、與輝瑞達成全球合作，創中國創新藥出海紀錄

2025年，三生制藥全球化戰略迎來關鍵突破，公司與輝瑞就自主研發的PD-1/VEGF雙抗SSGJ-707達成全球合作，成為生物醫藥行業年度標志性事件。

根據合作協議，三生制藥授予輝瑞SSGJ-707全球開發與商業化權利，交易總額最高超60億美元，公司同時享有基於全球累計收入的梯度雙位數分成。其中14億美元首付款及1億美元股權合作，一舉刷新中國創新藥單筆出海授權交易的首付款紀錄。這一重磅合作不僅獲得國際制藥巨頭對中國創新藥研發質量、標准及體系的高度認可，更充分彰顯了三生制藥乃至中國生物醫藥創新的全球競爭力。

此次合作中，三生制藥保留SSGJ-707在中國及全球臨床、商業化產品的供貨權利。目前，首批用於全球臨床開發的707雙抗原液已成功交付，標志著雙方合作正式進入實質性執行階段，全球商業化落地進程全面提速。

依托輝瑞全球頂尖的臨床資源，SSGJ-707的全球臨床高效推進，已啟動9項國際多中心臨床試驗，覆蓋鱗狀/非鱗狀非小細胞肺癌、轉移性結直腸癌、廣泛期小細胞肺癌、胃食管結合部癌、轉化型小細胞肺癌、局部晚期/轉移性肝細胞癌、局部晚期/轉移性尿路上皮癌、局部晚期/轉移性腎細胞癌等多個高發癌種。未來，還將持續拓展該品種更多適應症及聯用治療方案，充分釋放這一核心創新品種的全球臨床價值與商業增長空間。

二、創新價值密集兌現，構築新增長引擎

2025年至2026年初，三生制藥迎來產品獲批密集收獲期，三款新藥接連上市、核心產品獲批新適應症、商業化產品納入醫保目錄和權威指南、多款產品進入NDA階段，多維創新價值加速轉化，為業績持續增長注入強勁動力。

三款新藥接連獲批，豐富臨床治療選擇

安沐奇塔單抗（益賽拓®）：2026年2月獲批上市，用於治療中重度斑塊狀銀屑病。該產品第2周即起效、12周PASI100領先、52周持續清除，無中和抗體、ADA僅 0.7%，感染風險更低；維持期每8周一次的簡化給藥方案，大幅降低患者年度用藥頻率，有效減少長期治療的時間成本與心理壓力，顯著提升治療依從性。
羅賽促紅素α注射液（新比澳®）：2026年3月獲批上市，為首個國產長效重組EPO類雙周制劑（1類創新藥），用於治療慢性腎病引起的貧血且正在接受促紅細胞生成素治療的血液透析患者。產品擁有120小時超長半衰期、免疫原性低，靜脈給藥更適合血液透析患者，「兩周一次」 的給藥方案，大幅降低患者用藥頻次，顯著提升患者治療依從性，為臨床提供更便捷的治療選擇。
艾曲泊帕乙醇胺片：2026年3月獲批上市，用於治療免疫性血小板減少症（ITP）和重型再生障礙性貧血（SAA），為血液疾病患者提供口服用藥新選擇，進一步完善公司血液疾病領域商業化產品矩陣。 

核心產品拓展新適應症，挖掘存量市場增量空間

全球唯一商業化重組人促血小板生成素（特比澳®）於2025年12月獲批新適應症，用於計劃接受手術（含診斷性操作）的慢性肝病相關血小板減少症（CLDT）患者，為廣大圍手術期慢性肝病患者提供起效快、療效穩定、安全性高的升板治療方案，進一步拓展核心產品的市場覆蓋范圍。

商業化產品獲權威認可，加速臨床滲透

紫杉醇口服溶液（柏瑞素®）成功納入《CSCO胃癌診療指南（2025版）》，成為晚期胃癌患者二線治療的I級推薦（1A 類）方案；該產品也成功納入2025年國家醫保目錄。該產品依托創新性脂質自乳化藥物遞送技術，實現胃癌治療從 「住院輸注」 到 「居家口服」 的模式升級，大幅提升患者用藥便利性；目前其復發性或轉移性 HER2 陰性乳腺癌適應症NDA已遞交並獲受理，未來市場空間有望進一步打開。

三款產品進入NDA階段，後續增長動力充足

613（抗IL-1β單抗）：2025年6月急性痛風性關節炎NDA遞交並獲受理。中國急性痛風市場生物制劑滲透率極低，該產品為國內同類品種中第二家遞交上市申請，競爭格局優良，將填補臨床未被滿足的治療需求，市場前景廣闊。間歇性通風關節炎適應症II期臨床推進中。
611（抗IL-4Rα單抗）：2026年2月成人中重度特應性皮炎NDA遞交並獲受理。療效整體優於達必妥（非頭對頭對照），支持雙周或每四周一次長效給藥，療效更強、依從性更高、長期控制更優；慢性鼻竇炎伴鼻息肉、慢性阻塞性肺氣腫、青少年及兒童特應性皮炎等適應症臨床推進中，管線潛力持續釋放。
601A（抗VEGF單抗）：2025年10月視網膜分支靜脈阻塞（BRVO）所致黃斑水腫NDA獲受理。療效與雷珠單抗相當，總體安全性和耐受性良好，為眼科臨床提供新選擇。

三、構建多領域創新管線矩陣，築牢長遠核心競爭優勢

2025年，三生制藥持續加大研發投入，圍繞腫瘤血液科、自身免疫、腎科、皮膚毛發及減重等核心治療領域，構建起豐富且具有差異化的創新管線矩陣，多款產品處於關鍵臨床階段，前沿靶點布局領先，為公司長遠發展構築堅實的技術與產品壁壘。

腫瘤血液科：雙抗 / 三抗多點布局，打造差異化競爭優勢

705（抗PD1/HER2雙抗）：治療HER2陽性晚期實體瘤已進入II期臨床，為國內唯一積極推進臨床的同靶點藥物，差異化優勢顯著。
706（抗PD1/PDL1雙抗）：治療晚期非小細胞肺癌、晚期胃腸道腫瘤已進入 II 期臨床，覆蓋高發瘤種，臨床進展順利。
708（抗PD1/TGFβ雙抗）、709（抗PD1/LAG3雙抗）、SSS59（抗MUC17/CD3/CD28三抗）、SPGL008（抗B7H3抗體/IL15Rα sushi-IL15融合蛋白）治療晚期實體瘤，均處於I期臨床階段；SSS57（長效ActRIIB-Ig Trap融合蛋白）治療MDS相關貧血，處於I期臨床階段。腫瘤血液科管線梯隊持續完善，為長期增長儲備優質標的。 

自身免疫科：多款產品進入關鍵臨床階段，研發進度國內領先

610（抗IL-5單抗）：治療嗜酸性粒細胞哮喘處於III期臨床，研發進度國內第一，有望率先實現商業化。
626（抗BDCA2單抗）：治療系統性紅斑狼瘡（SLE）已進入Ib期臨床，針對自身免疫領域未滿足需求。
627（抗TL1A單抗）：治療潰瘍性結腸炎（UC）已啟動II期臨床，布局炎症性腸病核心賽道。   多款早研管線加速推進：包括716（抗OX40L/IL-31RA雙抗，治療AD）、717（CD3/CD19/BCMA，治療SLE/LN/RA）、718（TL1A/IL-23，治療IBD）、719（IL-4R/TSLP，治療哮喘/COPD）、629（IL-23R，治療銀屑病/ IBD）等，全面覆蓋自身免疫領域主流與前沿靶點，構建深厚技術護城河。

腎科：聚焦核心需求，前沿靶點布局國內首創

SSS55（C3b雙功能融合蛋白）：治療陣發性睡眠性血紅蛋白尿症（PNH）、補體相關腎病（CMKD）、牙周炎等適應症，已啟動I期臨床，為國內唯一積極推進該靶點的企業，填補國內臨床空白。
SSS68（長效抗April/BAFF雙抗）：治療IgA腎病已獲批美國IND，是目前在APRIL/BAFF靶點上唯一進入臨床階段的國產長效雙抗，差異化優勢顯著。
皮膚毛發及減重領域 前瞻布局
WS2403司美格魯肽減重適應症III期臨床試驗已完成。
WS204柯拉特龍乳膏劑治療12歲及以上中重度尋常性痤瘡III期臨床進行中。
SSS67（抗ActRIIA/ActRIIB雙抗）治療超重/肥胖症已獲批美國IND，是國內唯一進入IND申報的創新偏向型雙抗，前瞻性布局代謝領域藍海市場。

三生制藥董事局主席兼首席執行官婁競博士表示：「2025年是『十四五』規劃收官之年，在醫保、醫療、醫藥協同治理下，行業迎來多項標志性變革。商業健康險為創新藥打開多元支付通道，中國創新藥海外授權屢創佳績。公司自主研發的SSGJ-707以24%首付比創下出海授權新紀錄，彰顯中國創新的全球競爭力。2026年，生物醫藥被列為國家新興支柱產業，在國家政策推動下，產業正從制藥大國向醫藥強國邁進，公司的創新潛力亦獲國際認可。立足三十余年產業積澱，我們堅持守正創新，深耕腫瘤、自免、腎科等領域，加大前沿創新投入，持續優化研發管線，加快推進柏瑞素®、益賽拓®、新比澳®等新品上市推廣。在『讓創新生物藥觸手可及』的使命驅動下，推進更多優質品種早日上市，造福患者。」

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as a first-line treatment for patients with PD-L1–positive non-small cell lung cancer (NSCLC).

In the primary analyses of HARMONi-2, ivonescimab demonstrated a median progression-free survival (PFS) of 11.14 months compared with 5.82 months for pembrolizumab (HR = 0.51; P < 0.0001), representing a 49% reduction in the risk of disease progression or death, with a manageable safety profile. The exploratory analysis presented at ELCC 2026 focuses on the other key pillar of treatment evaluation: HRQoL. The HRQoL analysis was conducted with the QLQ-C30, QLQ-LC13, and EQ-5D-5L instruments, showed that in the chemotherapy-free setting, ivonescimab not only significantly extended PFS but also delivered meaningful improvements in health-related quality of life. These findings provide additional, robust evidence to support the broad clinical use of ivonescimab and reinforce its role as a new standard of care (SOC) in first-line lung cancer treatment.

Key Findings:

Global health and functional status with sustained improvements and delayed deterioration:

In the primary analysis of HARMONi-2,  in the ivonescimab group, the median time to deterioration (TTD) in global health status/quality of life (GHS/QoL) was not reached (vs 9.9 months for pembrolizumab), and the 12-month deterioration-free rate was 51% (vs 46%). The results published at ELCC2026, scores for GHS/QoL, physical function, and emotional function improved from baseline in both arms. In the ivonescimab arm, the mean GHS/QoL score increased from 71.8 (SD 17.6) at baseline to 78.5 (SD 15.9) at week 12 and remained stable at 78.5 (SD 16.0) at week 30. In the pembrolizumab arm, the mean score improved from 73.6 (SD 17.5) at baseline to 76.7 (SD 16.6) at week 12 and decreased slightly to 76.5 (SD 16.9) by week 30.

Better control of key lung cancer symptoms, with a sustained advantage in dyspnea:

According to the EORTC QLQ-LC13 lung cancer-specific questionnaire, patients in the ivonescumab group experienced sustained reductions in scores for cough, hemoptysis, and dyspnea.

Cough: Median TTD was not reached; the mean score decreased from 29.9 (SD 23.3) at baseline to 19.0 (SD 18.2) at week 12 and 19.6 (SD 21.7) at week 30.

Hemoptysis: The mean score decreased from 7.2 (SD 14.6) at baseline to 2.9 (SD 9.5) at week 30.

Dyspnea: Ivonescumab showed a trend toward superior long-term control, with the mean score decreasing from 17.5 (SD 16.0) at baseline to 12.1 (SD 14.6) at week 30.

High and stable health utility values:

On the EQ-5D-5L visual analog scale (VAS), the mean health status score increased from 81.9 (SD 13.5) at baseline to 84.3 (SD 10.6) at week 12 and remained high at 83.7 (SD 11.4) at week 30. Health utility values, which reflect overall patient well-being, remained consistently high throughout ivonescimab treatment, with mean values of approximately 0.9 (SD 0.1) at baseline, week 12, and week 30.

Based on the HARMONi-2 results, ivonescimab became the first therapy to show a significant PFS benefit over pembrolizumab in a head-to-head Phase III study. Ivonescimab was approved in 2025 in China as a first-line treatment for patients with PD-L1-positive NSCLC, establishing a novel,  more effective, and safer chemotherapy-free option. To date, the breakthrough clinical value of ivonescimab has been demonstrated in dozens of clinical trials and real-world experience involving more than 70,000 patients.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

香港2026年3月31日 /美通社/ -- 3月31日上午，復星國際董事長郭廣昌在復星國際2025年業績發佈會上表示，復星國際人民幣234億元的減值計提是「審慎的會計處理，不是經營出了問題」，這次減值是「晴天修屋頂」，管理層對未來發展有信心。

郭廣昌強調，從長遠來看，這次減值處理標誌着復星進入了全新發展階段。「我們堅決退出那些盈利不佳、價值不達標的資產，把資源聚焦到高增長的核心賽道，推動公司向更輕盈、更健康、更可持續的方向發展。」

他介紹，從復星各板塊的經營實績看，復星的核心產業經營穩健。醫藥板塊的全球化業務持續突破，多款產品在海外上市，也有多個有巨大潛力的在研管線；保險板塊境內外的業務都在增長，葡萄牙保險的業務拓展到拉美、非洲等區域，國內復星聯合健康、復星保德信人壽盈利大幅提升；旅文板塊的Club Med業績也創下了歷史新高。

「這些產業具備持續創造利潤和現金流的能力，是復星保持增長的底氣。這次大額減計後，未來的經營成果一定會更真實地體現復星核心產業的經營質量。我相信復星是有穿越週期的能力，短期內會有陣痛，但長遠來看，所做的這些都是為了復星走得更穩、走得更遠。」郭廣昌說。

他表示，復星管理層對公司未來的發展有確定性的預期，有充分信心。復星國際調整後淨資產價值（NAV）人民幣1,335億元，每股NAV達到港元18.1元。公司董事會已宣佈股份回購計劃，大股東和管理團隊也會進行增持。未來復星會結合經營改善和現金流狀況，積極研究並逐步推出更多回饋股東的舉措，包括優化分紅機制等等。

3月30日晚，復星國際公佈2025年業績。報告期內集團總收入達人民幣1,734.3億元，經調整產業運營利潤為人民幣40億元。四大核心子公司收入人民幣1,282億元，佔集團總收入的74%。其中，復星醫藥歸母淨利潤人民幣33.71億元，同比增長21.69%；復星葡萄牙保險歸母淨利潤達歐元2.01億元，同比增長15.8%。

和往年比較，復星整體業績數據保持穩健。不過這一年復星對部分存在減值跡象的地產項目及部分非核心業務板塊的商譽、無形資產進行了一次性非現金減值計提和價值重估，造成年度賬面虧損人民幣234億元，其中地產減值佔比為55%，非核心資產減值45%。

HONG KONG, March 31, 2026 /PRNewswire/ -- On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International's 2025 annual results presentation that the RMB23.4 billion impairment provision was a "prudent accounting measure, not a reflection of operational issues". He described the impairment as "repairing the roof on a sunny day" and said that the management is confident in Fosun's future development.

Guo Guangchang emphasized that, from a long-term perspective, this impairment marks Fosun's entry into a new stage of development. "We will resolutely divest assets with low profitability and value below target, and focus our resources on core, high‑growth areas, steering the Company toward a leaner, healthier, and more sustainable future."

He explained that the operating results of Fosun's various business segments indicate that Fosun's core businesses remain solid. The pharmaceutical business has continued to make breakthroughs in its global expansion, with multiple products launched overseas and several promising pipeline products. The insurance business saw growth both domestically and internationally, with Fosun Insurance Portugal expanding its business into regions such as Latin America and Africa. Meanwhile, domestic insurance companies, Fosun United Health Insurance and Pramerica Fosun Life Insurance, recorded significant profit increases. In the culture and tourism business, Club Med achieved record-high results.

"These businesses are capable of generating sustainable profit and cash flow, laying the foundation for Fosun's continued growth. Following this significant impairment, Fosun's future operating results will more accurately reflect the underlying quality of our core businesses. I believe Fosun has the ability to navigate through cycles. While we may face some short-term challenges, these efforts will position Fosun for steadier, longer-term growth," said Guo Guangchang.

He stated that Fosun's management has clear expectations and full confidence in the Company's future development. Fosun International's adjusted net asset value (NAV) was RMB133.5 billion, with a NAV per share reaching HKD18.1. The Company's Board of Directors has announced a share buyback program. Fosun's major shareholder and management team will also increase their holdings in the shares of the Company. In the future, Fosun will actively explore and gradually introduce further measures to reward shareholders, including optimizing the dividend mechanism, in line with operational improvements and cash flow conditions.

On the evening of 30 March, Fosun International announced its 2025 annual results. During the Reporting Period, the Group's total revenue reached RMB173.43 billion, and adjusted industrial operation profit was RMB4 billion. Its four core subsidiaries generated RMB128.2 billion in revenue, accounting for 74% of the Group's total revenue. Among them, Fosun Pharma achieved a net profit attributable to shareholders of the parent of RMB3.371 billion, representing a year-on-year increase of 21.69%. Fosun Insurance Portugal achieved a net profit attributable to owners of the parent of EUR201 million, up 15.8% year-on-year.

Compared to prior years, Fosun's results have largely remained stable. However, Fosun made non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators and goodwill and intangible assets of certain non-core business segments, resulting in a book loss of RMB23.4 billion in 2025, of which real estate-related impairment accounted for approximately 55%, while impairment of non-core assets accounted for approximately 45%.

BEIJING, March 31, 2026 /PRNewswire/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced that it will report its financial results for the third quarter ended February 28, 2026, before the U.S. market opens on April 22, 2026. New Oriental's management will host an earnings conference call at 8 AM on April 22, 2026, U.S. Eastern Time (8 PM on April 22, 2026, Beijing/Hong Kong Time). Participants can join the conference using the below options:

Dialling-in to the conference call:

Please register in advance of the conference, using the link provided below. Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.

Conference call registration link:
https://register-conf.media-server.com/register/BI2d1b37f83b4645f08b73fdd17af502f3. It will automatically direct you to the registration page of "New Oriental FY2026 Q3 Earnings Conference Call" where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial in number(s) and personal PIN) provided in the confirmation email received at the point of registering.

Joining the conference call via a live webcast:

Additionally, a live and archived webcast of the conference call will be available at http://investor.neworiental.org.

Listening to the conference call replay:

A replay of the conference call may be accessed via the webcast on-demand by registering at https://edge.media-server.com/mmc/p/7x5ve8hp first. The replay will be available until April 22, 2027.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

Contacts

For investor and media inquiries, please contact:

In China:

Ms. Sisi Zhao                                                                     Ms. Rita Fong
New Oriental Education and Technology Group Inc.         FTI Consulting                      
Tel:         +86-10-6260-5568                                              Tel:        +852 3768 4548                   
Email:     [email protected]                                                 Email:    [email protected]

HONG KONG, March 31, 2026 /PRNewswire/ -- Joyson Electronics (0699.HK/600699.SH) announced its FY2025 annual results. Its total revenue for the year reached RMB 61.2 billion, while profit attributable to shareholders was approximately RMB 1.34 billion, representing an increase nearly 40% YoY. Fresh orders (including autonomous driving) topped RMB 97 billion, once again setting a record high.

The company said its cost-efficiency initiatives gained traction in FY2025, supporting improved profitability. Profit totaled RMB 2.2 billion approximately, while adjusted profit attributable to shareholders came in at RMB 1.5 billion. Gross margin increased to 18.3%, improving by 2.1 percentage points from a year earlier, supported by operational optimization in overseas markets.

Moreover, Joyson Electronics also reported new orders of RMB 97 billion for the year, citing breakthrough in autonomous driving and cockpit–driving integration. Its first L3 intelligent driving domain controller is slated to enter mass production next year, while the L4 product is expected to be deployed in low-speed unmanned logistics vehicles.

Joyson is advancing intelligent driving on a "multi-chip platform + ecosystem collaboration" roadmap—deepening partnerships with algorithm players including Momenta and SENIOR, iterating L3/L4 ADAS functions, and working with chipmakers such as Qualcomm, NVIDIA, Horizon Robotics and Black Sesame Technologies. Joyson has made a strategic investment in Xinxin Hangtu, thereby establishing a full-stack intelligent driving solution spanning from entry-level to high-end offerings, and further extending its capabilities towards fully autonomous driving.

Looking ahead, the company said it expects further progress in L3/L4 intelligent driving in FY2026.

FY2025, Joyson invested around RMB 4.42 billion to accelerate R&D in new technologies, leveraging its automotive strengths to expand into next-generation agents, optical communications, and the server power infrastructure as new growth engines.

Meanwhile, Joyson Electronics is actively building positions in optical communications and server power, including the launch of an in-vehicle optical module co-developed with Zhongji InnoLight, a strategic investment in Fast Photonics to advance optical-module commercialization globally, and develop optical module manufacturing capacity in North America. Moreover, Joyson has developed server power solutions leveraging its automotive-grade technologies and capabilities.

The Company said that, leveraging the "One Joyson" global platform and its first-mover advantages of "China efficiency" and a global footprint, it is well positioned to support Chinese domestic brands in accelerating their overseas expansion, and to capitalize on incremental opportunities arising from the intelligent-vehicle upgrade in overseas markets.

About Joyson Electronics

Joyson Electronics (600699.SH / 0699.HK) is an intelligent automotive technology solution provider, offering advanced products and solutions across the auto electronics, auto safety, and next-generation agents. It has over 25 R&D centers and 60 production bases worldwide, serving more than 100 auto brands as customers.